Biosensors to Distribute Veryan's BioMimics 3D Stent

January 28, 2015—Biosensors International Group announced an agreement with Veryan Medical Ltd. to distribute Veryan’s BioMimics 3D, a nitinol stent with three-dimensional (3D) helical geometry designed for use in the superficial femoral artery. The agreement covers certain international markets but excludes the United States and Japan.

Biosensors expects to commence active promotion of BioMimics 3D in Q1 2015. The BioMimics 3D stent received CE Mark approval in September 2012.

According to the company, the BioMimics 3D stent incorporates Veryan’s 3D helical technology to promote natural swirling blood flow to elevate wall shear stress, which has been shown to reduce neointimal hyperplasia. The 3D design has also been shown to improve the biomechanical performance of the stent when implanted in the femoropopliteal artery, mitigating the risk of stent fracture and vessel kinking.

In November 2014, 2-year data from the MIMICS study of the BioMimics 3D stent were presented by Principal Investigator Professor Thomas Zeller, MD, during the late-breaking clinical trials session at the VIVA 2014: Vascular InterVentional Advances meeting in Las Vegas, Nevada. The findings demonstrate that the company’s BioMimics 3D nitinol stent provides a significant improvement in long-term primary patency compared to a straight nitinol control stent in patients undergoing femoropopliteal artery intervention.